Humacyte, Inc. (HUMA)

Humacyte's stock price on November 24, 2025, was $1.28, a decline from $4.28 on November 25, 2024, with a 52-week trading range between $1.09 and $6.77. The Q1 2025 earnings report was released on May 13, 2025. Humacyte held its Annual General Meeting on June 10, 2025, where stockholders approved the election of four Class I directors, ratified PricewaterhouseCoopers LLP as the independent auditor, and approved an amendment to increase the number of authorized shares of common stock from 250 million to 350 million. The Q2 2025 earnings report was released on August 11, 2025. In November 2025, Humacyte announced the publication of new data comparing Symvess™ to autologous vein in extremity arterial trauma and announced multiple presentations at the VEITHsymposium, highlighting positive clinical results for its Acellular Tissue Engineered Vessel (ATEV™). Humacyte announced its third-quarter financial results and provided a business update on November 12, 2025. Analyst sentiment indicates a "Moderate Buy" consensus rating with a price target of $8.29, suggesting a potential upside of approximately 523.0% from its current price of $1.33. However, short interest in Humacyte has recently increased by 3.64%, which may indicate decreasing investor sentiment.

Specific data regarding demand seasonality for Humacyte's products and services is not readily available. Demand for its specialized bioengineered tissues would likely be driven by clinical need, regulatory approvals, and market adoption rather than traditional seasonal consumer patterns.

Humacyte, Inc. is a biotechnology platform company focused on developing and manufacturing universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems. The company's primary product candidates are Human Acellular Vessels (HAVs), designed for implantation without immune rejection, and are being developed for various vascular applications. Humacyte is a clinical-stage biotechnology company that currently generates minimal revenue, primarily through research grants, as it focuses on developing and seeking regulatory approval for its HAVs.

Humacyte, Inc. is headquartered in Durham, North Carolina, United States. The company commenced the commercial launch of its Symvess product in the U.S. in late February 2025, with initial commercial shipments made to three Level 1 trauma centers. Humacyte has also engaged in a humanitarian program in Ukraine, providing investigational Acellular Tissue Engineered Vessels (ATEVs) to five hospitals on the frontlines for vascular trauma injuries, starting in June 2022.

Humacyte's brand reputation has been shaped by positive advancements and challenges. The company received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its ATEV in Vascular Trauma, AV Access, and PAD, which can accelerate development and review processes. The FDA also granted Priority Review for the Biologics License Application (BLA) for the HAV in the vascular trauma indication, with a PDUFA date set for August 10, 2024. The commercial launch of Symvess in the U.S. in late February 2025, following FDA release of the first commercial batch, marked a significant milestone. Positive clinical results for ATEV™ have been highlighted at scientific symposia, contributing to a favorable scientific reputation. However, Humacyte's reputation has also faced scrutiny due to a class action lawsuit alleging manufacturing deficiencies and market analysts expressing doubts about the company's near-term prospects.

Humacyte, Inc. has a diverse ownership structure comprising institutional, retail, and individual investors. There were 265 institutional owners holding a total of 54,353,256 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, Llc, State Street Corp, Morgan Stanley, UBS Group AG, and Woodline Partners LP. As of September 2025, 41 active institutional owners held 1.1% of the company's total shares outstanding, a decrease from 36.4% in June 2025. Bank of New York Mellon Corp was the largest institutional holder as of September 30, 2025, with 322.36K shares. Individual investors collectively hold approximately 41% of Humacyte's shares, making them the largest shareholder group. Insiders own about 1.63% of the company's stock. Fresenius Medical Care AG is also a significant shareholder, holding 14% of outstanding shares as of March 20, 2025.